Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8
Benzinga Newsdesk 10 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and raises the price target from $4 to $8.
Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight and raises the price target from $4 to $8.